natgillin/translations-raw huggingface dataset:
After release and absorption of the final dose the plasma concentration decreases, showing the same half-life values that were observed with oral formulations. 
Po sprostitvi in absorpciji zadnjega odmerka se plazemska koncentracija znižuje in kaže vrednosti razpolovne dobe, značilne za peroralne farmacevtske oblike.
In the event of overdose it is recommended to lay down the patient with elevated legs, for instance by using some pillows. 
V primeru prekomernega odmerjanja je priporočljivo, da bolnika položimo v ležeč položaj in dvignemo njegove noge (npr. z blazinami).
As a precaution, it is recommended to stop breast-feeding. 
Iz previdnosti je priporočljivo, da prenehate dojiti.
Co-administration of nifedipine with rifampicin is therefore contra-indicated. 
Hkratna uporaba nifedipina in rifampicina je zato kontraindicirana.
- The scope of the referral was to agree whether nifedipine should be contraindicated for women capable of childbearing or for nursing women and to amend the Summary of Products Characteristics in view of the available safety data 
- Namen napotitve je bil doseči soglasje o tem, ali naj bo uporaba nifedipina kontraindicirana pri ženskah v rodni dobi ali pri doječih materah ter ali naj se besedilo Povzetka glavnih značilnosti zdravila ustrezno spremeni glede na razpoložljive podatke o varnosti
Nifedipine Pharmamatch retard tablets must not be prescribed for these patients. 
Pharmamatch retard tablete se ne sme predpisati tem bolnikom.
Nifedipine is a calcium antagonist and has a spasmolytic effect on the vascular wall of mainly coronary arteries. 
Nifedipin je antagonist kalcijevih kanalčkov in ima spazmolitičen učinek na žilne stene, zlasti stene koronarnih arterij.
Separate analysis of the individual end-points show little differences in incidence between the groups treated with nifedipine or diuretics of stroke (2.0% versus 2.3%), MI (2.9% versus 2.7%) and death caused by any other cardiovascular disease (0.4% versus 0.4%). 
Ločena analiza posameznih opazovanih dogodkov med skupino bolnikov, ki so prejemali nifedipin, in skupino bolnikov, ki so prejemali diuretike, je pokazala majhne razlike v pojavnosti infarkta (2,0 % proti 2,3 %), miokardnega infarkta (2,9 % proti 2,7 %) in smrti zaradi katerekoli srčno-žilne bolezni (0,4 % proti 0,4 %).
Cardiogenic shock, clinically significant aortic stenosis, unstable angina pectoris, or during or within one month of a myocardial infarction. 
- Kardiogeni šok, klinično pomembna aortna stenoza, nestabilna angina pektoris ali v prvem mesecu po miokardnem infarktu.
There are situations when other treatment alternatives are not suitable or where calcium antagonists are appropriate to include in a combination of different drugs after careful benefit/risk evaluation. 
Obstajajo primeri, v katerih druge vrste zdravljenja niso ustrezne, ali kjer je po skrbnem vrednotenju razmerja med koristmi in tveganji antagoniste kalcijevih kanalčkov primerno vključiti v kombinacijo z drugimi zdravili.
Nifedipine Pharmamatch retard is formulated in such way that it releases the active substance in the intestine with a practically constant rate over a 16 to 18 hour time period. 
Zdravilo Nifedipine Pharmamatch retard je oblikovano tako, da sprošča svojo zdravilno učinkovino v črevesju s praktično stalno hitrostjo v časovnem obdobju 16 do 18 ur.
The use of rifampicin. 
- Jemanje rifampicina.
Do not take Nifedipine Pharmamatch retard - if you are allergic (hypersensitive) to nifedipine or any of the other ingredients of Nifedipine 
Ne jemljite zdravila Nifedipine Pharmamatch retard - Če ste alergični na (preobčutljivi za) nifedipin ali katerokoli sestavino zdravila Nifedipine
If you stop taking Nifedipine Pharmamatch retard If you suddenly stop using this medicine, the symptoms that you had before you started taking this medicine can come back. 
Če ste prenehali jemati zdravilo Nifedipine Pharmamatch retard Če nenadoma prenehate jemati zdravilo, se lahko znova pojavijo simptomi, ki ste jih imeli pred jemanjem tega zdravila.
If quinidine is added to an existing nifedipine therapy, blood pressure should be carefully monitored. 
Če obstoječemu zdravljenju z nifedipinom dodamo kinidin, moramo skrbno spremljati krvni tlak.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, NAČINOV UPORABE ZDRAVILA, VLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
3930 EB Woudenberg The Netherlands 
3930 EB Woudenberg Nizozemska
Co-administration of grapefruit juice reduces the first pass effect on nifedipine (see section 4.5). 
Sočasen vnos grenivkinega soka zmanjša učinek prvega prehoda za nifedipin (glejte poglavje 4.5).
When used concomitantly, nifedipine does not affect the pharmacokinetics of candesartancilexetil, cerivastatin or irbesartan. 
Pri sočasni uporabi nifedipin ne vpliva na farmakokinetiko kandesartancileksetila, cerivastatina ali irbesartana.
As a precaution, the patient should be examined for symptoms of digoxin overdose and, if necessary, a reduction of the glycoside-dosage should be considered, taking into account the plasma concentration of digoxin. 
Kot previdnostni ukrep je treba bolnika preiskati glede simptomov prekomernega odmerjanja digoksina in po potrebi znižati odmerek glikozida, pri čemer je treba upoštevati plazemske koncentracije digoksina.
When nifedipine is added to therapy with a diuretic, a temporary induced saluretic effect can occur, and a pre-existing hypokalaemia can be induced. 
Ko nifedipin dodamo zdravljenju z diuretikom, lahko pride do začasno induciranega saluretičnega učinka in indukcije že obstoječe hipokaliemije.
Use in children Nifedipine is not recommended for use in children 
Uporaba pri otrocih Nifedipina ni priporočljivo uporabljati pri otrocih.
Nifedipine is metabolised via the cytochrome P450 3A4 system (CYP3A4), which is present in the intestinal mucosa and the liver. 
Nifedipin se presnavlja prek sistema citokroma P450 3A4 (CYP3A4), ki se nahaja v intestinalni sluznici in v jetrih.
If you take too much nifedipine a low blood pressure (hypertension) can occur, which can be recognised from symptoms like dizziness, nausea, vomiting, drowsiness, confusion, lethargy, flushing, a lack of oxygen (hypoxia), headache or red spots on the face. 
Če ste vzeli preveč nifedipina, lahko pride do nizkega krvnega tlaka (hipotenzije), ki se kaže s simptomi, kot so omotica, slabost, bruhanje, zaspanost, zmedenost, letargija, rdečica, pomanjkanje kisika (hipoksija), glavobol in rdeče pike na obrazu.
In conclusion, the benefit/risk ratio favours the opinion that the use of nifedipine should not be contraindicated for women capable of childbearing or for nursing women. 
Razmerje med koristmi in tveganji je v prid mnenju, da uporaba nifedipina ni kontraindicirana pri ženskah v rodni dobi ali za doječe matere.
Blood pressure, ECG, central arterial pressure, pulmonary wedge pressure, urea and electrolytes should be monitored. 
Spremljati moramo krvni tlak, EKG, centralni arterijski tlak, pljučni zagozditveni tlak, sečnino in elektrolite.
Nifedipine can aggravate an existing decompensatio cordis in: patients with an obstruction of the out-flow tract, in which an increase of the gradient of the decompensation sometimes occurs (e.g. aorta stenosis) (See section 4.3); patients with a right-sided decompensatio cordis, in which in some cases a decrease of cardiac output, accompanied with increased fluid retention, occurs. 
Nifedipin lahko poslabša obstoječo dekompenzacijo srca pri: - bolnikih z obstrukcijo iztočne poti, pri kateri včasih prihaja do zvišanja gradienta dekompenzacije (npr. aortna stenoza) (glejte poglavje 4.3); - bolnikih z desnostransko dekompenzacijo srca, pri kateri včasih prihaja do zmanjšanja minutnega srčnega iztisa, kar spremlja povečano zastajanje tekočin.
Nifedipine is part of a group of medicines that relax and expand blood vessels (calcium antagonists). 
Nifedipin spada v skupino zdravil, ki sproščajo in raztegujejo žile (antagonisti kalcijevih kanalčkov).
Hypersensitivity to nifedipine or other dihydropyridines, or to any of the excipients. 
- Preobčutljivost za nifedipin ali druge dihidropiridine ali katerokoli pomožno snov.
The number of severe adverse events, as well as the number of reported metabolism-related adverse events such as hypokalaemia, hyponatraemia and hyperuremia, was lower in the group treated with nifedipine. 
Število hudih neželenih učinkov in število s presnovo povezanih učinkov, kot so hipokaliemija, hiponatriemija in hiperuremija, je bilo manjše v skupini bolnikov, zdravljenih z nifedipinom.
Published data show that in individual cases the tacrolimus dose can be reduced when co-administered with nifedipine. 
Objavljeni podatki kažejo, da se lahko v posameznih primerih odmerek takrolimusa zniža pri sočasnem dajanju z nifedipinom.
Preferably the tablets are administered in the morning with a glass of water (no grapefruit juice; see also section 4.5). 
Najbolje je, če bolnik tablete jemlje zjutraj s kozarcem vode (brez grenivkinega soka; glejte tudi poglavje 4.5).
The intake of grapefruit juice during treatment with nifedipine is discouraged (see also section 5.2). 
Vnos grenivkinega soka med zdravljenjem z nifedipinom ni priporočljiv (glejte tudi poglavje 5.2).
Bradycardia can be treated symptomatically with atropine or with β-sympathomimetics, like isoprenalin. 
Bradikardijo lahko zdravimo simptomatsko z atropinom ali β-simpatomimetiki, kot je izoprenalin.
If you forget to take Nifedipine Pharmamatch retard If you have forgotten to take Nifedipine Pharmamatch retard, then do so as soon as possible. 
Če ste pozabili vzeti zdravilo Nifedipine Pharmamatch retard Če ste pozabili vzeti zdravilo Nifedipine Pharmamatch retard, to storite čimprej.
In dialysis patients with malignant hypertension and hypovolaemia, a marked decrease in blood pressure can occur. 
Pri bolnikih na dializi z maligno hipertenzijo in hipovolemijo lahko pride do izrazitega znižanja krvnega tlaka.
The primary end-point was the combination of stroke, MI (including sudden death), heart failure or death from any other cardiovascular cause (composite end-point). 
Primarni opazovani dogodek je bila kombinacija infarkta, miokardnega infarkta (vključno z nenadno smrtjo), srčne odpovedi ali smrti s katerimkoli srčno-žilnim vzrokom (sestavljeni opazovani dogodek).
It is a fact that there are nifedipine products on the EU market which are not contraindicated neither in pregnancy nor in women capable of child bearing. 
Dejstvo je, da so na trgu zdravila, ki vsebujejo nifedipine in niso kontraindicirana niti v nosečnosti, niti pri ženskah v rodni dobi.
It is recommended to take the tablets in the morning with a glass of water (not grapefruit juice). 
Priporočljivo je, da tablete vzamete zjutraj s kozarcem vode (brez grenivkinega soka).
Nifedipine Pharmamatch retard should neither be prescribed to patients with Kock pouch (ileostomy after proctocolectomy). 
Zdravila Nifedipine Pharmamatch retard ne smemo predpisati bolnikom s "Kock pouch" (ileostomijo po proktokolektomiji).
Pharmamatch BV, Stationsweg Oost 281-D, 3931 ER Woudenberg, The Netherlands 
Pharmamatch BV, Stationsweg Oost 281-D, 3931 ER Woudenberg, Nizozemska
However, the CHMP does not find it justified to contraindicate use in nursing mothers. 
Kljub temu pa CHMP ne vidi dovolj dokazov za kontraindicirano uporabo pri doječih materah.
ATC code: C08CA05 
Farmakoterapevtska skupina: Zaviralci kalcijevih kanalčkov, Oznaka ATC: C08CA05
Do not use Nifedipine Pharmamatch retard after the expiry date which is stated on the label carton after “Expiry date” or “exp.”. 
Zdravila Nifedipine Pharmamatch retard ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »Expiry date« ali »exp.«.
If necessary, the nifedipine dosage should be reduced (see also subsection ‘Effects of Nifedipine Pharmamatch retard on other active substances'). 
Po potrebi odmerek nifedipina znižamo (glejte tudi razdelek »Učinki zdravila Nifedipine Pharmamatch retard na druge zdravilne učinkovine«).
Co-administration of nifedipine with 100 mg acetylsalicylic acid does not alter the effect of acetylsalicylic acid on platelet aggregation or bleeding time. 
Sočasno uporaba nifedipina in 100 mg acetilsalicilne kisline ne spremeni učinka acetilsalicilne kisline na agregacijo trombocitov in trajanje krvavitve.
Due to inhibition of the CYP3A4 system, cimetidine increases the plasma concentration of nifedipine, and therefore the antihypertensive effect of nifedipine may be potentiated. 
Zaradi zaviranja sistema CYP3A4 cimetidin zviša plazemsko koncentracijo nifedipina in s tem zveča antihipertenzijski učinek nifedipina.
- The active substance is nifedipine. 
- Zdravilna učinkovina je nifedipin.
exfoliative dermatitis, Steven-Johnsons syndrome, erythema multifome, urticaria, fixed drug eruption, pemphigus, phototoxicity. 
eksfoliativni dermatitis, Stevens-Johnsonov sindrom, multiformni eritem, urtikarija, fiksirane erupcije zaradi zdravil, pemfigus, fototoksičnost
Your doctor will determine the duration of treatment. 
Trajanje zdravljenja določi vaš zdravnik.
Co-administration of nifedipine with 100 mg acetylsalicylic acid, benazepril, candesartancilexetil, doxasozine, omeprazole, orlistat, pantoprazole, ranitidine, rosiglitazone or triamterene/hydrochlorothiazide does not affect the pharmacokinetics of nifedipine. 
Sočasna uporaba nifedipina in 100 mg acetilsalicilne kisline, benzaprila, kandesartancileksetila, doksazosina, omeprazola, orlistata, pantoprazola, ranitidina, roziglitazona ali triamteren/hidroklorotiazida ne vpliva na farmakokinetiko nifedipina.
Symptomatic treatment of chronic stable angina pectoris as monotherapy or in combination with a beta-blocker. 
Simptomatsko zdravljenje kronične stabilne angine pektoris v monoterapiji ali kombinaciji z zaviralci adrenergičnih receptorjev beta.
- Nifedipine Pharmamatch retard is used to treat high blood pressure (hypertension). 
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zdravljenje visokega krvnega tlaka (hipertenzije).
In patients with diarrhoea, the residence time of the tablet in the gastrointestinal tract, and as a result thereof, the duration of action are decreased. 
Pri bolnikih z drisko se skrajša zadrževalni čas tablete v gastrointestinalnem traktu in s tem tudi trajanje delovanja zdravila.
The pharmacokinetic properties of nifedipine in the Nifedipine Pharmamatch retard tablet are linear in a dose range of 30-180 mg. Based on the results of the bioequivalence studies, Nifedipine Pharmamatch retard tablets 30 mg and 60 mg can be considered to be bioequivalent to the reference product Adalat OROS under fasting and fed conditions. 
Farmakokinetične lastnosti nifedipina v zdravilu Nifedipine Pharmamatch retard tablete so premo sorazmerne v območju odmerkov 30-180 mg. Na podlagi rezultatov bioekvivalenčnih študij lahko Nifedipine Pharmamatch retard tablete 30 mg in 60 mg štejemo za bioekvivalentnega referenčnemu zdravilu Adalat OROS pri teščih in neteščih bolnikih.
Therefore, Nifedipine Pharmamatch retard is effective in angina pectoris and hypertension. 
Zato je Nifedipine Pharmamatch retard učinkovito zdravilo pri angini pektoris in hipertenziji.
Like all medicines, Nifedipine Pharmamatch retard can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Nifedipine Pharmamatch retard neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Therefore, a decrease or an increase in nifedipine plasma concentrations and hence an alteration in efficacy cannot be excluded. 
Zato ne moremo izključiti zvišanja oz. znižanja plazemskih koncentracij nifedipina ter s tem povezane spremembe učinkovitosti.
Endocrine disorders: - Rare: 
Bolezni endokrinega sistema: - Redki:
It is recommended to take the Nifedipine Pharmamatch tablets in the morning with a glass of water (not grapefruit juice). 
Najbolje je, če tablete Nifedipine Pharmamatch vzamete zjutraj s kozarcem vode (brez grenivkinega soka).
If necessary, your doctor can increase the dosage to 90 mg once-daily. 
Po potrebi lahko vaš zdravnik zviša odmerek na 90 mg enkrat dnevno.
Since it has been demonstrated that Nifedipine Pharmamatch retard tablets are bioequivalent with the nifedipine containing product Adalat OROS tablets, the Nifedipine Pharmamatch retard tablets are interchangeable with Adalat OROS tablets at all times. 
Ker so dokazali, da so Nifedipine Pharmamatch retard tablete bioekvivalenten zdravilu Adalat OROS tablete, ki vsebuje nifedipin, so Nifedipine Pharmamatch retard tablete v vsakem primeru zamenljive s tabletami Adalat OROS.
In severe cases, a lowering of the dose can be necessary. 
V hudih primerih je treba odmerek zmanjšati.
If you take more Nifedipine Pharmamatch retard than you should If you take more Nifedipine Pharmamatch retard than you should, immediately contact your doctor or pharmacist. 
Če ste vzeli večji odmerek zdravila Nifedipine Pharmamatch retard, kot bi smeli Če ste vzeli večji odmerek zdravila Nifedipine Pharmamatch retard, kot bi smeli, nemudoma obvestite svojega zdravnika ali farmacevta.
As a result of the relaxation of arterial muscle, nifedipine reduces peripheral resistance, leading to an improvement of peripheral blood flow whilst decreasing after-load. 
Posledica relaksacije mišic arterij je zmanjšanje perifernega žilnega upora, kar izboljša periferni krvni pretok in zmanjša breme (afterload).
Metabolic disturbances include hyperglycaemia, metabolic acidosis and hypo- or hyperkalaemia. 
- Presnovne motnje vključujejo hiperglikemijo, presnovno acidozo in hipo- ali hiperkaliemijo.
atrophic endometrium. 
atrofični endometrij
Symptoms of obstruction have also been seen in patients in which no gastrointestinal narrowing was diagnosed. 
O simptomih obstrukcije so poročali tudi bolniki brez diagnoze zoženja v prebavnih poteh.
Upon co-administration with rifampicin, the bioavailability of nifedipine is markedly reduced (95% decrease of AUC) and thus its efficacy weakened. 
Pri sočasni uporabi skupaj z rifampicinom se biološka uporabnost nifedipina močno zmanjša (95-% zmanjšanje AUC) in s tem tudi učinkovitost.
If you are on kidney dialysis please consult your doctor before taking this medicine. 
Če ste dializni bolnik, se posvetujte z vašim zdravnikom preden boste vzeli to zdravilo.
Taking Nifedipine Pharmamatch retard with food and drink The blood pressure lowering effect of nifedipine can be enhanced due to the intake of grapefruit juice. 
Jemanje zdravila Nifedipine Pharmamatch retard skupaj s hrano in pijačo Učinek nifedipina na zniževanje krvnega tlaka se lahko poveča pri zaužitju grenivkinega soka.
ventricular arrhythmias, conduction disturbances, exacerbation of supraventricular arrhythmias, digital blood flow reduction in patients with Raynaud's syndrome. 
prekatne aritmije, prevodne motnje, poslabšanje supraventrikularnih aritmij, zmanjšanje pretoka krvi v prste pri bolnikih z Raynaudovim sindromom
Simultaneous administration of quinupristin/dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine (Cmax increase of 33% compared to placebo). 
Zaradi sočasnega dajanja kombinacije kinupristin/dalfopristin in nifedipina se lahko zvišajo plazemske koncentracije nifedipina (zvišanje Cmax za 33 % v primerjavi s placebom).
Nifedipine can worsen an existing decompensatio cordis. 
Nifedipin lahko poslabša obstoječo dekompenzacijo srca.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKOV GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJE IN NAVODILA ZA UPORABO, PREDSTAVLJENI S STRANI EVROPSKE AGENCIJE ZA ZDRAVILA
Some studies reveal increased plasma concentrations of nifedipine in case of co-administration with quinidine, though others revealed no effects on the pharmacokinetic properties of nifedipine. 
V nekaterih študijah so odkrili zvišanje plazemske koncentracije nifedipina pri sočasni uporabi nifedipina in kinidina, v drugih pa učinkov na farmakokinetične lastnosti nifedipina niso dokazali.
Some of these substances, like fluoxetine, indinavir and ritonavir, have been demonstrated to inhibit the CYP3A4 mediated metabolism of nifedipine in vitro. 
Za nekatere od teh zdravilnih učinkovin, kot na primer fluoksetin, indinavir in ritonavir, so dokazali, da in vitro zavirajo presnovo nifedipina, posredovano s CYP3A4.
- Very rare: 
- Zelo redki:
Increased or decreased heart rates are also a symptom of overdosage. 
Simptoma prekomernega odmerjanje sta tudi pospešeno ali upočasnjeno utripanje srca.
dizziness, tiredness. 
omotica, utrujenost
Diltiazem decreases the clearance of nifedipine. 
Diltiazem zmanjša očistek nifedipina.
What Nifedipine Pharmamatch retard is and what it is used for Before you take Nifedipine Pharmamatch retard How to take Nifedipine Pharmamatch retard Possible side effects 
Kaj je zdravilo Nifedipine Pharmamatch retard in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Nifedipine Pharmamatch retard Kako jemati zdravilo Nifedipine Pharmamatch retard Možni neželeni učinki
Nifedipine Pharmamatch retard may be used alone, or in combination with a medicine from another group of medicines called β-blockers. 
Zdravilo Nifedipine Pharmamatch retard se lahko uporablja samo ali pa v kombinaciji z zdravilom iz druge skupine, ki ji pravimo zaviralci beta.
Nifedipine can further lower the blood pressure. 
Nifedipin lahko dodatno zniža krvni tlak.
In case of co-administration of nifedipine with β-blocking medicines, the patient should be carefully monitored, since severe hypotension can occur. 
V primeru hkratnega dajanja nifedipina in zaviralca beta je treba bolnika skrbno spremljati, ker lahko pride do hude hipotenzije.
Nifedipine can lower the chance of conception. 
Nifedipin lahko zmanjša možnost zanositve.
- Nifedipine Pharmamatch retard is used to reduce the frequency of occurence of a tight, painful chest ache caused by a shortage of oxygen in the heart muscle (angina pectoris). 
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zmanjšanje pojavnosti močnih bolečin v prsih, ki jih povzroča pomanjkanje kisika v srcu (angina pektoris).
angina upon abrupt withdrawal of nifedipine, increased frequency or worsening of angina, aggravation of myocardial ischemia including myocardial infarction, palpitations (tachycardia - accelerated pulse rate), congestive heart failure, hypotension, orthostatic hypotension. 
angina po hitri odtegnitvi nifedipina, zvišana pogostnost ali poslabšanje angine, poslabšanje miokardne ishemije (vključno z miokardnim infarktom), palpitacije (tahikardija - pospešeno utripanje srca), srčno popuščanje, hipotenzija, ortostatska hipotenzija
If the dose of nifedipine is increased during co-administration of both medicines, a reduction of the nifedipine dose should be considered when the treatment with phenytoin is discontinued. 
Če odmerek nifedipina med sočasno uporabo obeh zdravil zvišamo, je treba preučiti možnosti znižanja odmerka nifedipina po prekinitvi zdravljenja s fenitoinom.
Nifedipine is excreted into breast milk in small amounts. 
Nifedipin se v majhnih količinah izloča v materino mleko.
Additional fluids should be administered with caution to avoid cardiac overload. 
Dodatne tekočine je treba dajati previdno, ker se lahko pojavi preobremenitev srca.
Erythromycin, fluoxetine, protease-inhibitors and azole-derivatives No clinical interaction studies have been performed between nifedipine and active substances that inhibit the CYP3A4 system, like erythromycin, fluoxetine, protease-inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir) and azole-derivatives (ketoconazole, itraconazole and fluconazole). 
Eritromicin, fluoksetin, zaviralci proteaze in derivati azolov Kliničnih študij medsebojnega delovanja med nifedipinom in zdravilnimi učinkovinami, ki zavirajo sistem CYP3A4, kot so eritromicin, fluoksetin, zaviralci proteaze (amprenavir, indinavir, nelfinavir, ritonavir, sakvinavir) in derivati azolov (ketokonazol, itrakonazol in flukonazol), niso izvedli.